Inspiration meets innovation at Brandweek, the ultimate marketing experience. Join industry luminaries, rising talent and strategic experts in Phoenix, Arizona this September 23–26 to assess challenges, develop solutions and create new pathways for growth. Register early to save.
NEW YORK Four finalists are vying for the account of a new urinary incontinence drug from Eli Lilly & Co. and Boehringer Ingelheim, according to sources.
The estimated $25 million assignment is for ad duties outside the U.S.
Contending are WPP Group’s J. Walter Thompson in London, Omnicom Group’s BBDO in Dusseldorf, Germany, Interpublic Group’s Foote, Cone & Belding in New York and Havas’ Euro RSCG, London, sources said.
Final presentations are scheduled for mid-October at Boehringer Ingelheim’s headquarters in Ingelheim, Germany, said sources.
WORK SMARTER - LEARN, GROW AND BE INSPIRED.
Subscribe today!
To Read the Full Story Become an Adweek+ Subscriber
Already a member? Sign in